TALEN-mediated shift of mitochondrial DNA heteroplasmy in MELAS-iPSCs with m.13513G>A mutation

Area of Science:

• Stem cell biology
• Mitochondrial genetics
• Molecular medicine

Background:

• Mitochondrial diseases, often caused by mitochondrial DNA (mtDNA) mutations, pose significant research challenges.
• Induced pluripotent stem cells (iPSCs) offer a valuable platform for studying these genetic disorders.
• The MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) syndrome is a common mitochondrial disease linked to specific mtDNA mutations.

Purpose of the Study:

• To generate and characterize induced pluripotent stem cells (iPSCs) from a patient with MELAS carrying the m.13513G>A mtDNA mutation.
• To develop and test a mitochondrial DNA-targeted nuclease for reducing mutant mtDNA heteroplasmy in iPSCs.
• To evaluate the potential of this nuclease in understanding the pathological mechanisms of mtDNA-related diseases.

Main Methods:

• Reprogramming of patient dermal fibroblasts into iPSCs.
• Establishment of iPSC clones with varying levels of mutant mtDNA.
• Engineering of mitochondrially-targeted transcription activator-like effector nucleases (TALENs) to specifically recognize and cleave the m.13513G>A mutant mtDNA.
• Transduction of engineered TALENs into MELAS-iPSCs to assess their efficacy in reducing mutant heteroplasmy.

Main Results:

• Successful generation of iPSC clones from a MELAS patient, including those with and without the m.13513G>A mutation.
• Development of a novel TALEN (G13513A-mpTALEN) capable of targeting and cleaving the specific mutant mtDNA sequence within mitochondria.
• Demonstrated short-term reduction in the m.13513G>A heteroplasmy level in MELAS-iPSCs following TALEN transduction.

Conclusions:

• The generated iPSCs provide a robust model for studying MELAS and other mitochondrial DNA diseases.
• The developed mtDNA-targeted nuclease is a promising tool for manipulating mtDNA heteroplasmy levels in patient-derived iPSCs.
• This approach holds potential for advancing the understanding of mitochondrial disease pathogenesis and developing novel therapeutic strategies.